This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Diabetes Heart Failure Outcomes 
Heart BMJ
MARCH 26, 2025
Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. fold higher risk of heart failure with preserved ejection fraction (95% CI 1.30 m/s had a 2.10-fold
52 
Heart BMJ
MARCH 26, 2025
Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 Therefore, early identification of HF in high-risk populations, particularly post-MI, is essential for improving outcomes. HFrEF is more commonly.
HCPLive
MARCH 31, 2025
Justin Mark, MD, discusses an analysis of the FIGHT trial looking at racial and ethnic differences in heart failure outcomes.
Cardiovascular Diabetology
JANUARY 19, 2024
Diabetes mellitus (DM) is associated with a worse prognosis in patients with heart failure. Our aim was to analyze the clinical and imaging features of patients with DM and their association with outcomes in c.
95 
Cardiovascular Diabetology
AUGUST 6, 2024
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.
American College of Cardiology
NOVEMBER 7, 2024
The goal of the EMPEROR-Preserved trial was to assess the safety and efficacy of empagliflozin in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), irrespective of diabetes status.
Cardiovascular Diabetology
JUNE 6, 2024
Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outc.
64 
Cardiovascular Diabetology
APRIL 28, 2024
Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellit.
European Journal of Heart Failure
NOVEMBER 26, 2024
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association. 1.34), ischaemic heart disease (HR 1.20, 95% CI 1.09–1.31),
DAIC
APRIL 9, 2024
Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years.
HeartRhythm
APRIL 30, 2024
We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.
Open Heart
MAY 23, 2024
Background and aims Pre-eclampsia complicates 3–5% of pregnancies worldwide and is associated with adverse outcomes for the mother and the offspring. Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes.
European Journal of Heart Failure
FEBRUARY 25, 2025
Sodiumglucose cotransporter 2 (SGLT2) inhibitors in acute heart failure. Aims Results from randomized trials suggest benefit of sodiumglucose cotransporter 2 (SGLT2) inhibitor initiation in clinically stable acute heart failure. Follow-up started from discharge for maximum 1 year. There were 9641 eligible individuals.
Cardiovascular Diabetology
OCTOBER 31, 2024
The association between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) is unclear. This study aimed to investigate.
52 
Cardiovascular Diabetology
FEBRUARY 16, 2025
Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective factor against cardi.
Cardiovascular Diabetology
JULY 9, 2024
To adapt risk prediction equations for myocardial infarction (MI), stroke, and heart failure (HF) among patients with type 2 diabetes in real-world settings using cross-institutional electronic health records.
European Journal of Heart Failure
JANUARY 10, 2025
Abstract Aims In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic cardiovascular disease.
Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century. The use of MRAs has been limited due to excessive concern about hyperkalemia.
HeartRhythm
JANUARY 23, 2025
The prevalence of atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM) is reported to be higher than in the general population, ranging from 3.6% Also, the coexistence of T2DM and AF increases the risk of adverse cardiovascular events, including heart failure, atherosclerotic cardiovascular disease and mortality [2].
Hypertension Journal
NOVEMBER 22, 2023
BACKGROUND:Diabetes is an important risk factor for heart failure (HF) and is associated with left ventricular (LV) diastolic dysfunction. However, diabetic comorbid conditions, such as nocturnal hypertension, as predictors of diastolic dysfunction are not known in the absence of an HF period. Hypertension, Ahead of Print.
40 
Circulation: Cardiovascular Quality & Outcomes
FEBRUARY 8, 2024
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Background:Patients with type 2 diabetes are at risk of heart failure hospitalization. Accounting for all-cause mortality, we obtained the incidence for heart failure hospitalization at 5 years follow-up; overall and in each SDI group.
European Journal of Heart Failure
SEPTEMBER 26, 2023
Abstract Diagnosing heart failure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure. Use of this acronym would enable the early diagnosis of heart failure.
Journal of Cardiovascular Electrophysiology
MARCH 3, 2025
ABSTRACT Background Atrial fibrillation (AF) recurrence remains a significant challenge in heart failure with reduced ejection fraction (HFrEF) patients undergoing cryoballoon ablation (CBA). This study assesses the impact of SGLT2i on AF recurrence and clinical outcomes in HFrEF patients undergoing CBA. vs. 39.4%, p =0.036).
Heart BMJ
DECEMBER 15, 2023
Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heart failure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. Beta-coefficients (β-coef) are standardised. to 7.51, p=0.006).
Heart BMJ
JANUARY 10, 2024
Objective Identification of patients at risk of adverse outcome from heart failure (HF) at an early stage is a priority. Primary outcome was a composite of first hospitalisation for HF or all-cause mortality. Log-transformed GDF-15 was the strongest predictor of outcome (HR 2.12, 95% CI 1.71
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Cardiovascular Diabetology
OCTOBER 21, 2024
The therapeutic effects of ertugliflozin, a sodium-glucose cotransporter 2 inhibitor, on cardiovascular outcome are not fully understood. This study aimed to evaluate the efficacy and safety of ertugliflozin o.
Open Heart
JULY 20, 2022
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. Methods Patients acted as their own controls, with outcomes compared for equal periods (for each patient) pre (HF MDT) versus post-MDT (multispecialty) meeting. Results 334 patients (mean age 72.5±11
Circulation
NOVEMBER 11, 2024
Background:Heart failure (HF) is one of the leading causes of hospitalizations in the States. Patients with hyperkalemia had a higher frequency of diabetes mellitus, hypertension, chronic liver disease, acute kidney injury, chronic kidney disease, end-stage renal disease, and acute encephalopathy (p<0.001). 2], p<0.001).Conclusion:Hyperkalemia
40 
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
DAIC
FEBRUARY 29, 2024
This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly-anticipated clinical trials. 24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center.
103 European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Obesity was associated with more first and recurrent heart failure events. Overall, 60.9% of patients had BMI ≥30 kg/m 2.
CardiacWire
JANUARY 7, 2024
Applied Therapeutics saw its shares fall 40% late last week after revealing that its diabetic cardiomyopathy drug candidate AT-001 (caficrestat) didn’t meet its phase 3 trial’s primary endpoint. AT-001 is an investigational oral Aldose Reductase inhibitor being developed for the treatment of diabetic cardiomyopathy.
DAIC
JUNE 18, 2024
Smith Center for Outcomes Research in Cardiology and director of the cardiac critical care unit at Beth Israel Deaconess Medical Center in Boston, Mass. The diabetes rate is expected to rise from 16.3% Black children are expected to have the highest overall rates of high blood pressure and diabetes. "We and Susan F.
105 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
IntroductionThere is a higher prevalence of diabetes mellitus type 2 in Hispanics as compared to other ethnic groups in the United States. Diabetes is a risk factor for acute ischemic stroke and also a poor predictor of outcome for many interventional surgeries. or greater. vs. 20.5%; p = 0.048) and stenting (28.4%
40 Circulation
NOVEMBER 11, 2024
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among year follow-up time).Results:Among
40 
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Stroke Journal
JANUARY 30, 2025
Propensity score-matched analysis (PSM) (1:1) was performed on age, gender, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, LDL level, left ventricular ejection fraction and various drugs including beta blockers, ACEi and ARBi. 0.89), P<0.001), and after 1 year (RR, 0.91 (95% CI: 0.86-0.96),
Stroke Journal
JANUARY 30, 2025
Propensity score-matched analysis (PSM) (1:1) was performed with matching for age, gender, race, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, low-density lipid (LDL) level, left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and diuretics.
40 Journal of Cardiovascular Electrophysiology
JANUARY 9, 2025
Sodium-glucose co-transporter 2 inhibitors (SGLT2i), a novel class of antidiabetic drugs, have shown a promising impact in reducing cardiovascular events in diabetic and nondiabetic heart failure (HF) patients. Our study found that SGLT2 inhibitors significantly reduced AF recurrence post-CA in diabetic patients.
Heart BMJ
MAY 10, 2024
Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction. Arrhythmia prediction models have long relied on conventional risk factors such as age, diabetes, hypertension, and history of myocardial infarction and heart failure.
40 Stroke Journal
JANUARY 30, 2025
Background:The STRACK project aims to improve post-stroke patient management and the transition from acute to primary care thanks to improvements in patient pathways and monitoring cardiovascular risk factors: heart failure, diabetes, atrial fibrillation, dyslipidemia and hypertension.
40 
Journal of the American Heart Association
DECEMBER 29, 2023
AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.
45 
Journal of Cardiovascular Electrophysiology
NOVEMBER 5, 2023
Abstract Introduction Influence of early atrial fibrillation (AF) ablation, particularly cryoballoon ablation (CBA), on clinical outcome during long-term follow-up has not been clarified. The primary outcome was recurrence of atrial tachyarrhythmias (ATs) of ≥30-s after a 3-month blanking period.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content